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Abstract. Receptor Activator of NF-κB (RANK) and RANK-Ligand (RANKL) are members 
of the Tumour Necrosis Factor (TNF)-superfamily involved in bone homeostasis. In a tightly 
controlled interplay  of this receptor and ligand, bone is continuously being remodelled. Several 
pathological conditions resulting from a misbalance between bone resorption and bone 
formation have been documented. Most frequently resorption gets the overhand resulting in a 
lower Bone Mineral Density (BMD), increased fracture risk and reduced mobility of patients. 
RANKL is expressed on bone producing osteoblasts whereas RANK is exp ressed on pre-
osteoclasts, which can develop in bone resorbing osteoclasts. The binding of RANKL to 
RANK functions as a trigger fo r the format ion of these bone resorbing osteoclasts. With the 
development of a monoclonal antibody directed against RANKL a ne w therapeutic strategy to 
interfere with bone remodelling has become available  some years ago. In this manuscript we 
discuss the prospective of interfering with the RANK/RANKL pathway as a therapeutic target 
for bone diseases. We discuss the role of the soluble receptor osteoprotegerin (OPG) as a 
therapeutic in bone diseases. Then we focus on the possibility to develop antagonistic and 
agonistic variants of RANKL based on computational protein design and we discuss the 
development of antagonistic RANKL variants by changing the stoichiometry o f the RANKL 
molecule.  
1.  Introduction 
The Tumor Necrosis Factor (TNF) - superfamily is a group of cytokines consisting of ligands and 
receptors whose interactions regulate cell differentiation and controlled cell death (apoptosis) [1]. 
Thanks to their essential role in cell survival, many TNF-superfamily members are being investigated 
as potential therapeutic targets for diseases as diverse as cancer [2] and rheumatoid arthritis [3]. TNF-
superfamily members Receptor Activator of NF-κB (RANK), RANK Ligand (RANKL) and 
osteoprotegerin (OPG) have a role in proliferation of bone cells as they control the balance between 
bone producing osteoblasts and bone resorbing osteoclasts, thereby forming the human skeleton [4].  
From its appearance the skeleton seems to be a static structure, but bone tissue is continuously 
being remodelled. The complete human skeleton is renewed in approximately 10 years [5]. 
Remodelling is necessary to adapt to changes due to mechanical loads [6]. These lead to micro 
damage, which needs to be repaired to maintain the strength of the skeleton [7]. Differences in inter 
individual pressure on the skeleton lead to differences in bone remodelling. Individuals who exercise 
more and have more physical activity have a lower risk of fractures. Age related thinning of the bone 
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is associated with an increase in fragility of bone, which may result in fractures upon falling. By aging 
of our population bone diseases become more frequent [8].  
Bone diseases can be classified as syndromes with a lowered bone mass, with an increased bone 
mass and as bone tumours. In osteoporosis, there is an imbalance between osteoblastic and osteoclastic 
activity in favor of osteoclastic activity, leading to bone fragility and an increased risk of fractures [9]. 
Paget’s disease is the most common bone disease in which there is an increased bone mass. It is 
characterized by deformation of the bone.  Usually there are one or more focal areas of disorganized 
bone remodelling. Following osteoporosis, it is the most frequent bone disease [10]. Multiple 
myeloma is the most common primary malignancy of bone with marrow infiltration of the skeleton, 
which produces widespread osteolytic bone damage. In multiple myeloma , the balance between 
osteoblastic and osteoclastic activity is disturbed in favor of osteoclastic activity [11].  
Recently, the first biological -denosumab, an antibody directed against RANKL- was introduced 
and accepted by legal authorities for treating osteoporosis. The monoclonal antibody (mAB) interferes 
with the RANK/RANKL signalling and thereby inhibits not only osteoclast activity [12] but also bone 
tumours [13]. Recent discoveries such as the structure of RANKL bound to RANK and OPG have 
given further insight into the molecular mechanisms of RANK/RANKL and OPG in bone 
remodelling, elucidating key residues interaction of the ligand and the receptors [14-17].  
This review will focus on strategies to combat bone diseases making use of the RANK/RANKL 
pathway. We will discuss the process of RANK/RANKL controlled bone remodelling in the next 
paragraph and will thereafter discuss mechanisms of action of (new) therapeutic options to treat bone 
diseases interfering with this pathway. 
2.  RANK/RANKL/OPG controlled bone remodelling 
Osteoblasts originate from pluripotent mesenchymal cells. Osteoblast cells are responsible for the 
formation, deposition and mineralization of bone tissue [18]. Bone is an important source for calcium 
and phosphate and as such important for mineral homeostasis [19]. Parathyroid Hormone (PTH) is a 
key regulator of calcium metabolism. When blood calcium levels are reduced, PTH is produced and 
secreted thereby increasing osteoclast mediated bone resorption which increases calcium levels [20].  
RANK and its corresponding ligand RANKL play a role in bone homeostasis by tightly controlling 
the balance between bone resorbing osteoclasts and bone producing osteoblasts. Upon activation by 
PTH, RANKL is presented on the surface of osteoblasts [5]. RANK is presented on the surface of pre-
osteoclasts upon binding of a paracrine factor, Macrophage Colony Stimulating Factor (M-CSF) [21]. 
Osteoblasts secrete M-CSF, which in turn binds to its corresponding receptor M-CSFR on pre-
osteoclasts activating the RANK/RANKL pathway [22]. 
Interaction between RANKL and RANK leads to fusion of the osteoclast precursors resulting in 
multinucleated mature osteoclasts having the capability to resorb bone. Upon RANKL binding to 
RANK, TNF receptor associated factor-1 (TRAF1), -2, -3, -5, and -6 are recruited to the intracellular 
domain of RANK [23]. TRAF6 seems to be the most important of these as recruitment leads to the 
activation of nuclear factor κ (NF-κB) [24]. NF-κB in turn regulates transcriptional activity of 
osteoclast-specific proteins [25]. Osteoprotegerin (OPG) acts as a decoy receptor for RANKL thus 
preventing interaction between RANK and RANKL resulting in less fusion of the OPCs [26]. The 
RANK-RANKL pathway is important in bone development in both physiological and pathological 
situations. Therefore, this signal pathway can be considered as a promising target for bone-related 
diseases [27].  
 
3.  Interfering with the RANK/RANKL pathway in combatting bone diseases 
3.1.  Antagonizing RANKL 
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The natural antagonist for suppressing RANKL titers is OPG. This soluble receptor of the TNF family 
is present at high concentrations in bone and it plays a natural role in protecting bone mass, hence, its 
name osteoprotegerin. OPG and RANK bind to slightly different regions of RANKL. RANK 
distributes its contacts evenly around the DE-loop and A’A’’-loop of RANKL. In contrast the contacts 
made by OPG are limited to the E-strand and DE-loop region of RANKL, almost completely avoiding 
the A’A’’-loop region [14]. OPG exerts its function as decoy receptor by blocking residues essential 
for RANKL to bind RANK [28]. Initial trials to use OPG as a therapeutic have failed due to the poor 
pharmacokinetic and pharmacodynamic properties and due to interference with the heparin binding 
domain in mice [29]. As a result, numerous fusion proteins containing a variety of residues of human 
OPG fused to human Fc fragments were tested and some were found to be 200 times more active than 
full-length OPG in vivo. A recombinant Fc-OPG, AMGN-0007, was in phase I clinical study for 
osteolytic bone metastasis and was discontinued due to the potential safety risk of immune response 
[30]. The human RANKL binding domain of RANK fused Fc fragment (RANK-Fc) was also found to 
be more effective than native OPG. However, in primates, following repeated dosing of human 
RANK-Fc, inactivating autoantibody titers against RANK were detected and the development was 
discontinued. Subsequently, monoclonal antibodies were selected and one monoclonal antibody 
obtained from immunization of the IgG2 XenoMouse emerged as a potent inhibitor of RANKL 
induced osteoclast formation. The resulting monoclonal antibody (an IgG2κ antibody) was originally 
designated AMG 162 and is now known as denosumab. Alternatively, peptide mimics of OPG (OP3-4 
peptide) [31], RANK [32] and the tumour necrosis factor (TNF) receptor (WP9QY peptide) [33] were 
also developed. Although they showed inhibitory activity against the RANKL-induced 
osteoclastogenesis, further research of them is needed before these can be applied for therapeutic 
treatment. 
The use of OPG in bone malignancies is limited as OPG also functions as a decoy receptor for 
Tumour Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) as well, preventing the 
apoptosis of tumour cells[34]. Therefore, structure-based OPG mutants have been designed that still 
do antagonize RANKL inhibiting osteoclastogenesis , but which do not bind TRAIL and therefore do 
not interfere with tumour apoptosis [34]. TRAIL cancer therapy has been shown to be effective. 
Recombinant human TRAIL variants with a decreased affinity for OPG have been investigated and 
this research was done to overcome TRAIL resistance when applied in the bone environment [35].  
3.2.  Antagonizing RANK 
One other approach to target bone diseases is to target and antagonize RANK directly. The advantage 
of targeting the receptor over targeting the ligand RANKL can be found in the direct inactivation of 
the receptor. Although denosumab titrates away RANKL, it does not block the receptor.  Furthermore 
the administration of antibodies such as denosumab carries the risk of immune reactions [36]. 
Compared with antibody, administration of structure-based protein mutants are most likely to trigger 
the auto immune system with less impact, as the mutations in the proteins involve less residues. 
Therefore, the design of antagonistic proteins based on the RANKL seems to be an attractive 
approach.  
The feasibility to design variants of TNF-ligands with altered binding properties was first shown 
for TRAIL[37]. In many cancer cells, apoptosis seems to occur primarily via only one of the two 
TRAIL death receptors and the introduction of receptor selectivity is a way to create more potent 
TRAIL agonists. With computational protein design it is possible to predict protein segments and 
amino acids important for binding, affinity and strength of the ligand-receptor complexes [38]. All 
residues in the receptor binding interface can be mutated into any possible other amino acid. A set of 
predicted energetic values for the wild type TRAIL - receptor complex formation was compared with 
the obtained energetic values after mutagenesis. The change in binding energy at every residue can be 
used as a prediction for improved or decreased binding. Afterwards predicted variants were expressed, 
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purified and screened for receptor selectivity by surface plasmon resonance (SPR). TRAIL variants 
selective for a specific TRAIL death receptor could be obtained this way [37, 39-40]. 
Due to the high homology among TNF ligands and their cognate receptors, an alternative strategy 
to predict variants with agonistic or antagonistic properties is to compare different TNF-superfamily 
members; interaction domains and interacting residues do show similarity among TNF ligand-receptor 
complexes. One of these interaction loops is the so called DE-loop. There is a conserved tyrosine in 
the DE-loop of all TNF-ligands except CD40L and RANKL. Shibata and others found that mutations 
in this hydrophobic residue of the DE-loop in TNF-α yielded TNF-receptor 1 selective antagonist [41].  
The 3D structure of the complex between RANK and RANKL suggests that hydrophilic interactions 
are predominant among all the surface interactions between the DE-loop of RANKL and RANK. 
However, RANKL mutation at the equivalent residue 248 from isoleucine to aspartate resulted in an 
eightfold lower activity [16]. Then, the effect of further mutations at position I248 in the DE-loop of 
murine RANKL on the interaction of RANKL with RANK was investigated. RANKL I248Y and 
I248Kwere found to compete with wild-type RANKL binding to RANK while reducing wild-type 
RANKL-induced osteoclastogenesis [42]. These mutations suggest that the DE-loop of RANKL is 
important for osteoclastogenesis and two newly formed mutants, RANKL I248Y and I248K, can offer 
a starting point for novel therapeutic proteins in new osteoporosis treatments (Figure 1) 
 
Figure 1. Structural overview of the area surrounding the DE loop of (A) Refined structure of 
RANKL (orange) -RANK (green) complex. The DE loop of RANKL is shown in yellow. The figure 
was derived from the known structure of RANK: RANKL complex (PDB ID: 4GIQ). (B) Close-up 
view of residues near I248 in the DE-loop of RANKL Changes in the stoichiometry of the receptor. 
3.3.  Changes in the stoichiometry of the receptor 
An important characteristic of the TNF superfamily is the multimeric organization of receptors and 
ligands. For RANK and RANKL a trimeric RANK receptor binds to a trimeric RANKL ligand; this is 
needed for the biological effect [43]. RANK trimerizes through hydrophobic interactions at the core of 
the trimer, leading to assembly of a homotrimer [16]. However, TNF ligands can also bind to their 
corresponding monomeric and dimeric receptor subunits. It was found that there is a high affinity for 
the first binding to a monomeric subunit of the receptor. Using Surface Plasmon Resonance a high 
affinity binding between RANKL and the first monomeric subunit of RANK was demonstrated. A 
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 could be 
calculated [44].  
The development of RANKL variants occupying only one monomer of the RANK receptor 
obstructing the binding to three monomeric RANK receptors will have an antagonistic effect on 
osteoclast formation [45]. By creating RANKL variant that only has a single intact receptor binding 
interface, one RANK receptor might still be bound but additional receptor molecules can no longer be 
recruited to form the biologically active trimeric receptor complex. This leaves less receptor molecules 
available to trimerize. Thus, these variants do not only block RANK-RANKL interaction by 
competition with trimeric RANKL but also leave less RANK receptor molecules available on the cell 
surface. 
Interestingly, monoclonal antibodies, such as denosumab, bind to trimeric TNF family members 
mostly in a 3:2 complex, meaning 3 denosumab antibody molecules bind two RANKL molecules 
(trimeric), resulting in complicated kinetics [46]. Compared with the antibodies, structure-based 
variants binding in a 1:1 complex might exhibit simpler kinetics resulting in a reduction of the risk of 
side effects. 
4.  Conclusion 
The TNF-superfamily members RANKL and RANK are important for bone remodelling. Their roles 
in osteoclast derived bone resorption have been the subject of study for a long time. With the 
development of a monoclonal antibody derived against RANKL, a new therapeutic approach to 
combat bone diseases became available. In the review we presented three ways to develop new 
possible therapeutics to interfere with RANK/RANKL signalling. First, we focused on the possibility 
to use OPG, the natural decoy receptor for RANKL. Then we discussed the development of RANKL 
variants with antagonistic properties, based on computational design using conserved domains in the 
TNF-superfamily. Finally, we discussed antagonistic molecules interfering with the trimerization of 
RANK, a conformation essential for signal transduction. Interfering with the RANK/RANKL pathway 
is a promising strategy to develop therapeutics to combat bone diseases. 
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